345 related articles for article (PubMed ID: 24162006)
1. Management of Kawasaki disease.
Eleftheriou D; Levin M; Shingadia D; Tulloh R; Klein NJ; Brogan PA
Arch Dis Child; 2014 Jan; 99(1):74-83. PubMed ID: 24162006
[TBL] [Abstract][Full Text] [Related]
2. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease.
Tang B; Lo HH; Lei C; U KI; Hsiao WW; Guo X; Bai J; Wong VK; Law BY
Phytomedicine; 2020 Apr; 70():153208. PubMed ID: 32283413
[TBL] [Abstract][Full Text] [Related]
4. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children.
Chen MR; Kuo HC; Lee YJ; Chi H; Li SC; Lee HC; Yang KD
Front Immunol; 2021; 12():632890. PubMed ID: 33732254
[TBL] [Abstract][Full Text] [Related]
5. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
6. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
[TBL] [Abstract][Full Text] [Related]
7. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
8. Adjunctive therapies for Kawasaki disease.
Campbell AJ; Burns JC
J Infect; 2016 Jul; 72 Suppl():S1-5. PubMed ID: 27241708
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
Wu Y; Liu FF; Xu Y; Wang JJ; Samadli S; Wu YF; Liu HH; Chen WX; Luo HH; Zhang DD; Wei W; Hu P
Clin Exp Med; 2019 May; 19(2):173-181. PubMed ID: 30617865
[TBL] [Abstract][Full Text] [Related]
10. Management of acute and refractory Kawasaki disease.
Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
[TBL] [Abstract][Full Text] [Related]
11. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
Chantasiriwan N; Silvilairat S; Makonkawkeyoon K; Pongprot Y; Sittiwangkul R
Paediatr Int Child Health; 2018 Aug; 38(3):209-212. PubMed ID: 29768976
[TBL] [Abstract][Full Text] [Related]
12. Japanese Kawasaki Disease Scoring Systems: Are they Applicable to the Iranian Population?
Edraki MR; Mohammadi H; Mehdizadegan N; Ghorashi M; Amoozgar H; Borzouee M; Ajami G; Keshavarz K; Dehghani E; Bahrami R
Arch Iran Med; 2020 Jan; 23(1):31-36. PubMed ID: 31910632
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
Zhu BH; Lv HT; Sun L; Zhang JM; Cao L; Jia HL; Yan WH; Shen YP
Eur J Pediatr; 2012 Mar; 171(3):571-8. PubMed ID: 22057683
[TBL] [Abstract][Full Text] [Related]
14. Kawasaki disease: 40 years after the original report.
Gedalia A
Curr Rheumatol Rep; 2007 Aug; 9(4):336-41. PubMed ID: 17688844
[TBL] [Abstract][Full Text] [Related]
15. Predicting IVIG resistance in UK Kawasaki disease.
Davies S; Sutton N; Blackstock S; Gormley S; Hoggart CJ; Levin M; Herberg JA
Arch Dis Child; 2015 Apr; 100(4):366-8. PubMed ID: 25670405
[TBL] [Abstract][Full Text] [Related]
16. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
[TBL] [Abstract][Full Text] [Related]
17. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
Tremoulet AH; Jain S; Kim S; Newburger J; Arditi M; Franco A; Best B; Burns JC
Contemp Clin Trials; 2016 May; 48():70-5. PubMed ID: 27080929
[TBL] [Abstract][Full Text] [Related]
18. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
Friedman KG; Gauvreau K; Baker A; Son MB; Sundel R; Dionne A; Giorgio T; De Ferranti S; Newburger JW
Arch Dis Child; 2021 Mar; 106(3):247-252. PubMed ID: 32943389
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the treatment of Kawasaki disease.
Weng KP; Ou SF; Lin CC; Hsieh KS
J Chin Med Assoc; 2011 Nov; 74(11):481-4. PubMed ID: 22100015
[TBL] [Abstract][Full Text] [Related]
20. Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease.
Zhang RL; Lo HH; Lei C; Ip N; Chen J; Law BY
Curr Opin Pharmacol; 2020 Oct; 54():72-81. PubMed ID: 32956895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
